Aeterna Zentaris Inc. (AEZS) has advanced 5.44% at $0.35 in pre-market trading hours on the last check Thursday. Aeterna Zentaris (AEZS) stock lost -0.97% to complete the last trading session at $0.34. The price range of the company’s shares was between $0.3333 and $0.3519. It traded 0.86 million shares, which was below its daily average of 1.79 million shares over 100 days. AEZS’s shares have dropped by -7.68% in the last five days, while they have lost -19.93% in the last month. Aeterna Zentaris stock is gaining traction before it participates in a virtual event.
Which event AEZS will be taking an interest in?
Aeterna Zentaris (AEZS) is a specialty biopharmaceutical organization creating and commercializing a broadened arrangement of drug and indicative items zeroed in on areas of critical neglected clinical need. AEZS’ lead item, macimorelin (Macrilen), is the solitary U.S. FDA and European Commission supported oral test demonstrated for the conclusion of grown-up development chemical lack (AGHD).
Aeterna Zentaris (AEZS) is utilizing the clinical achievement and convincing wellbeing profile of macimorelin to foster it for the finding of adolescence beginning development chemical lack (CGHD), an area of huge neglected need, in a joint effort with Novo Nordisk.
Aeterna Zentaris (AEZS) is set to partake in a virtual event one week from now. JTC Team (“JTC”), a completely coordinated corporate correspondences and financial backer relations firm, has as of late declared it will have the Virtual Investor 2022 Top Picks Conference January 25-27, 2022.
- As a component of the virtual occasion, JTC joined forces organizations including AEZS will give a corporate show, trailed by an intelligent Q&A meeting.
- All financial backers and invested individuals will have the potential chance to submit inquiries to Aeterna Zentaris (AEZS) live during the event.
- Furthermore, intrigued members may likewise pre-submit inquiries before the live event, which can be sent through the meeting site at virtualinvestorco.com.
- AEZS will respond to whatever number of inquiries as would be prudent during the event, plan on Wednesday, January 26, 2022, at 9:00 AM ET.
- Aeterna Zentaris (AEZS) Chief Executive Officer Dr. Klaus Paulini as of late presented at the virtual H.C. Wainwright BioConnect Conference that occurred on January 10-13, 2022.
Aeterna Zentaris plan after the event
A video webcast of the Aeterna Zentaris (AEZS) presentation is accessible on the Events page in the Investors segment of the Company’s site. AZES will file the webcast replay for 90 days following that event.
